Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Song, Lelea; b; * | Yu, Haotiana | Jia, Jiaa; c | Li, Yuemina; *
Affiliations: [a] The Chinese PLA 309th Hospital, Beijing 100091, China | [b] BioChain (Beijing) Science and Technology, Inc., Beijing 100176, China | [c] Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei 075000, China
Correspondence: [*] Corresponding authors: Yuemin Li, Department of Radiotherapy, The Chinese PLA 309th Hospital, No. 17, Heishanhu Road, Haidian District, Beijing 100091, China. Tel.: +86 10 66775222; E-mail: [email protected]. Lele Song, Department of Radiotherapy, The Chinese PLA 309th Hospital, No. 17, Heishanhu Road, Haidian District, Beijing 100091, China. Tel.: +86 13240149188; E-mail: [email protected]
Abstract: BACKGROUND: The applications of the SEPT9 assay are expanding from CRC early diagnosis to screening, therapeutic effect monitoring and prognosis prediction. Its performance in these areas has not been thoroughly examined. OBJECTIVE: We aim to evaluate the performance of the SEPT9 assay in CRC screening, diagnosis and therapy by reviewing the current data published in these aspects. METHODS: The Ovid MEDLINE, EMBASE, CBMdisc (China Biology Medicine disc) and CJFD (Chinese Journal Full - text Database) database were searched for potential reports on the assay performance. Letters, reviews, meta-analysis and guidelines, basic research studies and articles irrelevant to mSEPT9 detection assays were excluded. Finally, data from 19 studies was summarized and systematically reviewed to clarify the assay performance. RESULTS: 2/3 algorithm provided the best overall performance in diagnosis and screening, while the 1/3 algorithm exhibited the best sensitivity in screening. The combination of SEPT9 assay with FIT and/or CEA enhanced the CRC detection rate in screening. The SEPT9 assay appeared to be effective in monitoring the therapeutic effect and may potentially predict the CRC recurrence and survival. CONCLUSION: The SEPT9 assay exhibited satisfactory performance in CRC diagnosis and screening, while more evidence is needed for therapeutic effect monitoring and prognosis prediction.
Keywords: SEPT9, Septin 9, colorectal cancer, adenoma, methylation, CEA, fecal DNA
DOI: 10.3233/CBM-160321
Journal: Cancer Biomarkers, vol. 18, no. 4, pp. 425-432, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]